After earning his medical degree (MBBS) from the University of Western Australia, Dr John Cullity undertook advanced training in haematology-oncology at QEII Medical Center. He then moved to the United Kingdom to complete Royal College of Physicians examinations. He also completed a Master of Science at the London School of Economics and an MBA at The Wharton School, University of Pennsylvania.
After a period consulting to World Health Organisation and The World Bank, Dr Cullity worked as a director of Health Economics (Oncology) & Strategic Pricing at Schering-Plough, and then for seven years at Sanofi-Aventis as director of Health Economics (Oncology), senior director and head of strategic pricing, and senior director of business development & licensing (Oncology).
Between 2010 and 2017 in New York, Dr Cullity was a principal for Torreya Partners, the internationally-recognised transactions firm where he managed numerous licensing/M&A transactions and participated in the establishment of several biotech companies. He remains a director of Theraly Fibrosis (spin-out from Johns Hopkins University), Haemalogix (Australian immune-oncology company) and Ceramedix Holdings (spin-out from Memorial Sloan Kettering Cancer Center).
